Cost of Generic Dapagliflozin
Generic dapagliflozin 10 mg costs approximately $352 per month (30-day supply) based on the most recent National Average Drug Acquisition Cost (NADAC) data from 2024-2025.
Detailed Pricing Information
Based on the most recent American Diabetes Association Standards of Care guidelines 1:
Current Pricing (2024-2025 Data)
- NADAC (actual acquisition cost): $352 per month for 10 mg daily dosing
- AWP (wholesale price): $664-$678 per month for 10 mg daily dosing
- The NADAC represents what pharmacies actually pay and is more reflective of real-world costs to patients
Historical Pricing Trends
The cost of dapagliflozin has shown variation over recent years:
- 2023: NADAC $527-$543/month 2, 3
- 2022: NADAC $511/month 4
- 2021: NADAC $496/month 5
- 2020: NADAC $473/month 6
- 2019: NADAC $446/month 7
The recent decrease to $352/month in 2024-2025 likely reflects increased generic availability and market competition 1.
Important Context
Comparison to Other SGLT2 Inhibitors
Among SGLT2 inhibitors (2024-2025 NADAC pricing) 1:
- Dapagliflozin 10 mg: $352/month (most affordable)
- Ertugliflozin 15 mg: $343/month
- Empagliflozin 25 mg: $586/month
- Canagliflozin 300 mg: $574/month
Cost Caveats
- These prices represent average acquisition costs and do not account for:
- Individual insurance coverage and copays
- Pharmacy-specific discounts
- Manufacturer rebates or patient assistance programs
- Geographic variation
- Actual out-of-pocket costs to patients may differ substantially from these figures
Clinical Value Consideration
While cost is important, dapagliflozin has demonstrated significant cardiovascular and renal benefits in major trials (DAPA-HF, DAPA-CKD, DECLARE), which should be weighed against medication costs when making treatment decisions 2, 1.
The approximately $352/month cost represents a meaningful reduction from previous years, making this evidence-based therapy more accessible for patients requiring SGLT2 inhibitor therapy.